Treatment With Pirfenidone for COVID-19 Related Severe ARDS
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
A randomized, open label, two arm, pilot trial of Pirfenidone 2,403 mg administered per
nasogastric tube or orally as 801mg TID for 4 weeks in addition to Standard of Care (SoC),
compared to SoC alone, in a population of COVID-19 induced severe ARDS. Patients will be
randomized according to 1:1 ratio to one of the trial arms: Pirfenidone (intervention arm) or
SoC (control arm).